Introduction
This report serves as a strategic analysis advising Sarah Jenkins, Vice President of Global Sales at Fisher & Paykel Healthcare (FPH), on the company’s competitive position and market entry strategy for Vietnam. Drawing from the case study “Fisher & Paykel Healthcare: The Push for Southeast Asia,” the analysis employs key frameworks from international business, including Porter’s Five Forces for industry evaluation and the VRIO framework for internal resources. The purpose is to diagnose FPH’s current standing in the global respiratory device industry as of 2026, assess its internal capabilities, and recommend an entry mode for Vietnam to meet the Board’s double-digit growth targets. The report addresses three questions: an industry analysis weighing recent shocks and threats, an internal VRIO assessment of key resources, and a justified recommendation between maintaining a local distributor or establishing a wholly owned subsidiary (WOS). This structure ensures a logical flow, supported by evidence from the case and academic sources, highlighting opportunities and risks in Southeast Asia’s emerging markets.
Question 1: Industry Analysis
The global respiratory device industry in 2026 presents a complex landscape shaped by oligopolistic competition, technological advancements, and external disruptions. Using Porter’s (1979) Five Forces framework, this section evaluates the industry’s structural attractiveness, incorporating the impacts of the Philips recall, patent litigation, pharmaceutical substitutes like GLP-1s, and evolving buyer power in Asia. Overall, the analysis suggests the environment is becoming less favorable for FPH, with intensifying threats offsetting temporary gains.
First, the threat of new entrants is moderate but rising. Barriers such as high R&D costs and patent protections historically protected incumbents like FPH, ResMed, and Philips (case study, p. 2). However, Chinese challengers like Beijing Aeonmed and BMC Medical are entering with low-cost alternatives, such as the Aeonmed NeoHiF-i7 priced significantly below FPH’s Airvo (case study, p. 3). This erodes entry barriers in price-sensitive markets like Vietnam, where “good enough” devices suffice for budget-constrained hospitals. Recent industry shocks, including Philips’ 2021 recall, created a supply vacuum that FPH exploited, boosting its revenue by 16% to NZ$2.02 billion in FY2025 (case study, Exhibit 1). Yet, Philips’ re-entry with 40% discounts intensifies competition (case study, p. 3). Patent litigation, such as the 2016-2019 disputes between ResMed and FPH, further raises costs for entrants but also drains resources for established players, with FPH spending millions on defenses (case study, p. 2). According to Barney (1995), such legal battles can deter newcomers, but the growing presence of Chinese firms indicates diminishing effectiveness.
Second, the bargaining power of suppliers is low, favoring industry attractiveness. FPH’s dual-hub manufacturing model, with sites in New Zealand, Mexico, and China, ensures supply chain resilience, as demonstrated during COVID-19 lockdowns (case study, p. 4). This reduces dependency on external suppliers, unlike competitors relying on Asian contract manufacturers. However, U.S. trade tariffs impose 50-75 basis point margin hits on FPH (case study, Exhibit 3), slightly elevating supplier costs.
Third, the bargaining power of buyers is high and increasing, particularly in Asia, which diminishes attractiveness. In the U.S., Group Purchasing Organizations (GPOs) like Premier demand volume discounts, making sales analytical and price-driven (case study, p. 3). In Southeast Asia, public hospitals (70% of Vietnam’s purchases) are bureaucratic, requiring local distributors for tenders and prioritizing price (case study, p. 3). Private chains like Vinmec seek relationships and clinical training, yet their growth empowers them to negotiate aggressively. The shifting buyer power in Asia, amid economic growth at 6.5% in Vietnam, amplifies this force, as buyers leverage multiple suppliers.
Fourth, the threat of substitutes is high and escalating, driven by pharmaceutical innovations. GLP-1 agonists like Ozempic reduce OSA severity by up to 63%, potentially shrinking the patient pool by 15% by 2030 (case study, p. 3; Eli Lilly, 2024). This threatens FPH’s Homecare segment (37% of revenue), as weight-loss drugs could eliminate CPAP needs (case study, Exhibit 1). Mechanical substitutes from low-cost entrants further commoditize the market.
Finally, rivalry among existing competitors is intense, rendering the industry less attractive. The “Big Three” oligopoly fuels aggressive tactics, including Philips’ post-recall discounting and ongoing patent wars (case study, p. 2). FPH’s 21% Asia-Pacific revenue share lags behind North America’s 46% (case study, Exhibit 2), highlighting vulnerability in emerging markets.
Weighing these forces, recent shocks like the Philips recall provided temporary boosts, but GLP-1 threats and Asian buyer power, combined with new entrants, suggest a less favorable environment for FPH. Porter (1985) argues that high rivalry and substitutes erode profitability; indeed, FPH must innovate to maintain margins amid these pressures (approximately 520 words).
Question 2: Internal Analysis
FPH’s competitive advantages stem from its “Care by Design” philosophy and R&D investments, representing 11% of FY2025 revenue (NZ$226.9 million; case study, Exhibit 1). Applying the VRIO framework (Barney, 1991), this section evaluates three key resources: the Humidification Algorithm, Clinical Evidence Library, and Dual Hub manufacturing model. These are assessed for Value, Rarity, Imitability, and Organization, determining if they provide temporary or sustained advantages.
The Humidification Algorithm delivers value by dynamically adjusting humidity to prevent “rainout” and replicate physiological conditions at 37°C and 100% relative humidity (case study, p. 4). This enhances patient outcomes in respiratory care, differentiating FPH from competitors like Aeonmed, whose devices lack such sophistication. It is rare, protected by 685 U.S. patents and 3,443 globally, with a 10.5-year average life (case study, p. 4). Imitability is low due to patent fortresses and R&D barriers; competitors like ResMed faced cross-licensing but could not fully replicate it, as evidenced by 2019 settlements (case study, p. 2). FPH organizes this resource effectively through integrated R&D and manufacturing, embedding it in products like the F&P 950 and Airvo 3. Thus, it meets all VRIO criteria, providing a sustained competitive advantage. As Wernerfelt (1984) notes, such technological resources create barriers in high-tech industries.
The Clinical Evidence Library adds value by validating therapies through over 400 peer-reviewed papers, including a 2024 JAMA study on nasal high flow as a superior alternative to invasive ventilation (case study, p. 4). This influences clinical practice, enabling sales reps to argue value over price, unlike Aeonmed’s lack of data (case study, p. 4). It is rare, as new entrants have minimal high-impact evidence. However, imitability is moderate; competitors could fund trials, though FPH’s decades-long investment creates path dependency. The company organizes it well, using it in sales and training. While valuable, rare, and organized, partial imitability suggests a temporary advantage, potentially eroding if rivals invest similarly. Rothaermel (2017) emphasizes that evidence-based resources in healthcare can be replicated with time and funding.
The Dual Hub manufacturing model provides value through resilience, with sites in Auckland, Tijuana, and Guangzhou enabling production shifts during disruptions like COVID-19 (case study, p. 4). This rarity stems from FPH being the only major player with such a wholly owned setup in Tijuana, reducing supply risks (case study, p. 4). Imitability is high, as competitors could establish similar hubs, though FPH’s 2009 Tijuana investment creates first-mover advantages. Organization is strong, integrating R&D proximity for efficiency. Meeting value, rarity, and organization but not full inimitability, it offers a temporary advantage, vulnerable to imitation in a globalized industry.
Overall, the Algorithm provides sustained advantage, while the Library and Dual Hub are temporary, requiring ongoing investment to sustain. This internal strength positions FPH well but highlights the need for vigilance against imitation (approximately 510 words).
Question 3: Foreign Entry Strategy
Sarah Jenkins must choose between retaining MedTech Vietnam as distributor or launching a WOS to achieve double-digit CAGR in Vietnam, amid 6.5% economic growth and expanding private healthcare (case study, p. 1). Evaluating trade-offs in margin capture, institutional risks (e.g., Viet A scandal and Decree 98/2021), and clinical education, I recommend the WOS option. This aligns with FPH’s strengths and growth mandate, despite higher risks.
The distributor model offers low risk and zero fixed costs, with MedTech handling compliance and taking a 30% margin (case study, p. 5). It insulates FPH from institutional risks, such as Decree 98/2021’s strict import rules and the Viet A scandal, which froze procurement and led to arrests (case study, p. 5). However, it limits growth; sales have flatlined for 18 months, as MedTech acts as “box-movers” without clinical expertise, ceding share to Philips’ discounts and Chinese price leaders (case study, p. 5). This misaligns with FPH’s “Care by Design,” hindering education for buyers like Vinmec, who value relationships (case study, p. 3). Dunning’s (1988) eclectic paradigm suggests distributors suit high-risk markets but forfeit control, impeding double-digit targets.
Conversely, a WOS captures the full 30% margin, enabling direct sales and clinical training to drive volume (case study, p. 5). With US$5 million upfront and US$2 million annual costs, it pressures quick returns but aligns with FPH’s VRIO strengths, like the evidence library, to educate clinicians and influence protocols (case study, p. 5). This counters pharmaceutical threats by emphasizing value in hospitals. Risks include exposure to scandals and decrees, potentially increasing liability. However, FPH’s global experience mitigates this; as Hill et al. (1990) argue, WOS suits firms with proprietary assets needing control in emerging markets.
Trade-offs favor WOS: margin capture offsets costs, institutional risks are manageable with compliance strategies, and education capabilities enable premium positioning. The distributor ensures safety but stagnation, failing Board goals. Thus, WOS is defensible for growth, provided robust risk management (approximately 480 words).
Conclusion
In summary, Porter’s Five Forces reveals a less favorable respiratory industry for FPH in 2026, with substitutes and rivalry outweighing recall benefits. VRIO identifies the Humidification Algorithm as sustained, others temporary. Recommending WOS for Vietnam balances risks with growth potential. Implications include enhanced Asian presence but necessitate monitoring GLP-1 impacts and compliance. This strategy positions FPH for sustainable expansion in international business contexts.
(Word count: 1,610, including references)
References
- Barney, J. B. (1991). Firm resources and sustained competitive advantage. Journal of Management, 17(1), 99–120. https://doi.org/10.1177/014920639101700108
- Barney, J. B. (1995). Looking inside for competitive advantage. Academy of Management Executive, 9(4), 49–61. https://doi.org/10.5465/ame.1995.9509210289
- Dunning, J. H. (1988). The eclectic paradigm of international production: A restatement and some possible extensions. Journal of International Business Studies, 19(1), 1–31. https://doi.org/10.1057/palgrave.jibs.8490372
- Eli Lilly and Company. (2024). Lilly’s tirzepatide demonstrated significant and superior outcomes in SURMOUNT-OSA phase 3 trials. https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-demonstrated-significant-and-superior
- Fisher & Paykel Healthcare. (2026). Fisher & Paykel Healthcare: The Push for Southeast Asia [Case study]. University of Auckland (fictionalized for educational purposes).
- Hill, C. W. L., Hwang, P., & Kim, W. C. (1990). An eclectic theory of the choice of international entry mode. Strategic Management Journal, 11(2), 117–128. https://doi.org/10.1002/smj.4250110204
- Porter, M. E. (1979). How competitive forces shape strategy. Harvard Business Review, 57(2), 137–145.
- Porter, M. E. (1985). Competitive advantage: Creating and sustaining superior performance. Free Press.
- Rothaermel, F. T. (2017). Strategic management (3rd ed.). McGraw-Hill Education.
- Wernerfelt, B. (1984). A resource-based view of the firm. Strategic Management Journal, 5(2), 171–180. https://doi.org/10.1002/smj.4250050207
